Skip to main
RLYB
RLYB logo

Rallybio Corp (RLYB) Stock Forecast & Price Target

Rallybio Corp (RLYB) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Rallybio Corp's Phase 1b proof-of-concept data for RLYB212 demonstrates a promising capability to swiftly eliminate transfused HPA-1a+ platelets, suggesting its potential as a preventative treatment for fetal and neonatal alloimmune thrombocytopenia (FNAIT), a condition currently lacking FDA-approved therapies. The initiation of dosing in the first pregnant woman at high risk for FNAIT marks a significant milestone, reflecting both the company's commitment to advancing innovative therapies and the considerable risk mothers are willing to take for potentially life-saving treatments for their unborn children. Additionally, the financial model indicates optimism regarding Rallybio's future placement in the market, highlighting a supportive outlook for development and approval pathways, particularly regarding RLYB116 for paroxysmal nocturnal hemoglobinuria (PNH).

Bears say

Rallybio Corp reported a net loss of $0.25 per share, indicating ongoing financial challenges as the company develops therapies for rare disorders. The company faces multiple risks, including potential delays in clinical trials and the possibility of unfavorable clinical data for key pipeline candidates, RLYB212 and RLYB116. Additionally, risks associated with partnerships and the prospect of long-term dilution contribute to a negative outlook for Rallybio's stock performance.

Rallybio Corp (RLYB) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rallybio Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rallybio Corp (RLYB) Forecast

Analysts have given Rallybio Corp (RLYB) a Buy based on their latest research and market trends.

According to 6 analysts, Rallybio Corp (RLYB) has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rallybio Corp (RLYB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.